Boehringer Ingelheim

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Therapeutic Area

Metabolic

Cardiovascular

Oncology

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.
See All Products

Products

Metabolic

View

Empagliflozin

Linagliptin

Inflamation

View

Nintedanib

Oncology

View

Giotrif

Cardiovascular

View

Dabigatran etexilate

Telmisartan

Pradaxa

View

Dosing Calculator

Respiratory

View

Tiotropium + Olodaterol
Resources
Contact
Logout

Boehringer Ingelheim

Efficacy
About Pulmonary Fibrosis
Expert View
RA-ILD risk calculator

Nintedanib

Nintedanib

The Importance of Prompt Treatment of IPF

03/02/2023 | Author: Boehringer Ingelheim

Document ID: PC-MY-102861

About Pulmonary Fibrosis

A1-R101||A2-R101||How to recognize pulmonary fibrosis on HRCT scans (Rheum)

A1-R101||A2-R101||Time is of the essence: Suspect fibrotic interstitial lung disease

A1-R101||A2-R101||ILD in SSc & when to consider treatment by Dr. E. Volkmann

A1-R101||A2-R101||Risk factors for Progressive RA-ILD by Dr. E. Volkmann

A1-R101||A2-R101||Importance of MDD for managing CTD-ILD patients by Dr E. Volkmann

The Importance of Prompt Treatment of IPF

RELATED CONTENT

PC-MY-103434-thumbnail

PDF

A1-R101||A2-R101||How to recognize pulmonary fibrosis on HRCT scans (Rheum)

Download Opens in new tab

PC-MY-103435

PDF

A1-R101||A2-R101||Time is of the essence: Suspect fibrotic interstitial lung disease

Download Opens in new tab

EM-MY-100276

3:43

A1-R101||A2-R101||ILD in SSc & when to consider treatment by Dr. E. Volkmann

Watch now Opens in new tab

EM-MY-100278

3:57

A1-R101||A2-R101||Risk factors for Progressive RA-ILD by Dr. E. Volkmann

Watch now Opens in new tab

EM-MY-100277

1:43

A1-R101||A2-R101||Importance of MDD for managing CTD-ILD patients by Dr E. Volkmann

Watch now Opens in new tab

Home
Inflammation
nintedanib
About Pulmonary Fibrosis
The Importance of Prompt Treatment of IPF

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

This website is intended for healthcare professionals in Malaysia. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.

Copyright © 2024 Boehringer Ingelheim (Malaysia) Sdn Bhd.
All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement.